Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2023-07-01
2024-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ESP vs SPSIP Block in VATS Analgesia
NCT07232940
US-Guided SAPB Versus ESPB on Acute and Chronic Pain After VATS
NCT05160961
Comparison of Erector Spinae Block and Combined Deep and Superficial Serratus Anterior Plane Block
NCT06073197
Serratus Posterior Superior Intekcostal Plane Block vs Serratus Anterior Plane Block for Postoperative Analgesia in VATS: A Randomized Trial"
NCT07020624
Erector Spinae Plane Block and Thoracal Paravertebral Block Following Video Assisted Thoracic Surgery
NCT03854773
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Block Techniques
All blocks were performed following surgical closure, prior to extubation, with the patient in lateral decubitus and the skin prepared with 10% povidone-iodine.
ESPB was performed in 15 patients. An ultrasound (USG) probe was placed in a sagittal orientation at the T5 level, 3 cm lateral to the midline, to visualize the transverse process. The trapezius, rhomboid major, and erector spinae muscles were identified. Using an in-plane technique, a needle was advanced cranio-caudally through these muscles until it reached the transverse process. After negative aspiration, 30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
SAPB: The latissimus dorsi and serratus anterior muscles were identified at the midaxillary line at the 4th-5th rib level in a longitudinal parasagittal orientation. A needle was advanced from caudal to cranial using an in-plane approach, first targeting the plane between the latissimus dorsi and serratus anterior, and then deep to the serratus anterior. After negative aspiration, 10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
SPSIPB: The USG probe was placed 2-3 cm medial to the scapular spine to visualize the trapezius, rhomboid major, and serratus posterior superior muscles. At the level of the 2nd-3rd ribs, a needle was advanced into the plane between the serratus posterior superior muscle and the rib. After confirming negative aspiration, 30 mL of 0.25% bupivacaine was injected.
All blocks were performed unilaterally, targeting the surgical hemithorax.
Postoperative Analgesia and Assessments
Twenty minutes before extubation, all patients received 1 g IV paracetamol and 50 mg IV dexketoprofen. In the recovery room, patient-controlled analgesia (PCA) with IV tramadol hydrochloride was initiated (4 mg/mL concentration, 10 mg bolus, 20-minute lockout, maximum 3 boluses/hour).
Postoperative VAS scores (static at rest and dynamic during movement or coughing) were recorded at 0, 1, 6, 12, 18, and 24 hours. The first VAS assessment (0 hour) was performed when the patient achieved an Aldrete score of 9. If VAS ≥ 4, an additional 1 g IV paracetamol (maximum 3 g/day) was administered. Additional analgesic consumption was recorded. Side effects such as nausea, vomiting, and pruritus were documented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESP block
Erector spinae plane (ESP) block was performed in 15 patients. An ultrasound (USG) probe was placed in a sagittal orientation at the T5 level, 3 cm lateral to the midline, to visualize the transverse process. The trapezius, rhomboid major, and erector spinae muscles were identified. Using an in-plane technique, a needle was advanced cranio-caudally through these muscles until it reached the transverse process. After negative aspiration, 30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle. The block was performed unilaterally, targeting the surgical hemithorax.
Erector Spinae Plane Block
30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
SAP block
Serratus anterior plane (SAP) block was performed in 15 patients. The latissimus dorsi and serratus anterior muscles were identified by using USG at the midaxillary line at the 4th-5th rib level in a longitudinal parasagittal orientation. A needle was advanced from caudal to cranial using an in-plane approach, first targeting the plane between the latissimus dorsi and serratus anterior, and then deep to the serratus anterior. After negative aspiration, 10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine. The block was performed unilaterally, targeting the surgical hemithorax.
Serratus anterior plane block (SAP)
10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
SPSIP block
The USG probe was placed 2-3 cm medial to the scapular spine to visualize the trapezius, rhomboid major, and serratus posterior superior muscles. At the level of the 2nd-3rd ribs, a needle was advanced into the plane between the serratus posterior superior muscle and the rib. After confirming negative aspiration, 30 mL of 0.25% bupivacaine was injected. The block was performed unilaterally, targeting the surgical hemithorax.
Serratus posterior superior intercostal plane block
30 mL of 0.25% bupivacaine was injected into the plane between the serratus posterior superior muscle and the rib.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erector Spinae Plane Block
30 mL of 0.25% bupivacaine was injected deep to the erector spinae muscle.
Serratus anterior plane block (SAP)
10 mL was injected into the superficial plane and 20 mL into the deep plane, for a total of 30 mL of 0.25% bupivacaine.
Serratus posterior superior intercostal plane block
30 mL of 0.25% bupivacaine was injected into the plane between the serratus posterior superior muscle and the rib.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* morbid obesity (BMI \> 40 kg/m²),
* body weight ≤ 50 kg,
* skin infection at the block site,
* refusal to participate,
* inability to cooperate during postoperative pain assessment,
* conversion to open surgery,
* preexisting pain,
* known allergy to any study medication,
* coagulopathy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cumhuriyet University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oguz Gundogdu
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oğuz Gündoğdu
Role: PRINCIPAL_INVESTIGATOR
Sivas Cumhuriyet University School of Medicine, Anesthesiology and Reanimation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sivas Cumhuriyet University
Sivas, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-05/04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.